{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:35:42Z","timestamp":1649075742925},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,7,3]],"date-time":"2005-07-03T00:00:00Z","timestamp":1120348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00404-005-0024-z","type":"journal-article","created":{"date-parts":[[2005,7,6]],"date-time":"2005-07-06T13:03:20Z","timestamp":1120655000000},"page":"192-194","source":"Crossref","is-referenced-by-count":0,"title":["Case ReportWeekly carboplatin in a frail elderly woman with advanced peritoneal carcinoma"],"prefix":"10.1007","volume":"273","author":[{"given":"Benjamin","family":"Piura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Meirovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,7,3]]},"reference":[{"key":"24_CR1","doi-asserted-by":"crossref","unstructured":"The International Collaborative Ovarian Neoplasm (ICON) Group (1998) ICON 2 randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 352:1571\u20131576","DOI":"10.1016\/S0140-6736(98)04119-1"},{"key":"24_CR2","doi-asserted-by":"crossref","unstructured":"The International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cispaltin in women with ovarian cancer: the ICON 3 randomized trial. Lancet 360:505\u2013515","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"24_CR3","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2018Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"24_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(01)00340-9","volume":"38","author":"AH Calvert","year":"2002","unstructured":"Calvert AH, Egorin MJ (2002) Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. European Journal of Cancer 38:11\u201316","journal-title":"European Journal of Cancer"},{"key":"24_CR5","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1200\/JCO.2003.06.077","volume":"21","author":"M Gore","year":"2003","unstructured":"Gore M (2003) Carboplatin equals cisplatin: but how do I prescribe it? J Clin Oncol 21:3183\u20133185","journal-title":"J Clin Oncol"},{"key":"24_CR6","doi-asserted-by":"crossref","unstructured":"Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F on behalf of the Associazone per la Ricerca in Ginecologica Oncologica (ARGO 96) Study Group (2001) Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81:3\u20139","DOI":"10.1006\/gyno.2001.6151"},{"key":"24_CR7","unstructured":"Gonzalez-Martin AA, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balana C, Gonzalez MC, Herrero A, Pelegri A, Cervanes A (2003) Randomized phase II study of carboplatin (C) versus paclitaxel-carboplatin (PC) in platinum-sensitive (PS) recurrent advanced ovarian carcinoma (AOC) with assessment of quality of life (QoL): A GEICO (Spanish Group for Investigation on Ovarian Carcinoma) study. 2003 American Society of Clinical Oncology (ASCO) Annual Meeting. Proc Am Soc Clin Oncol 22:451 (Abstract 1812)"},{"key":"24_CR8","doi-asserted-by":"crossref","unstructured":"Van der Burg ME, Vergot I, Burger CW, Van der Gaast A (2004) Phase II study of weekly paclitaxel and carboplatin in the treatment of progressive ovarian cancer. 2004 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol (Post-Meeting Edition) 22:14S (Abstract 5058)","DOI":"10.1200\/jco.2004.22.14_suppl.5058"},{"key":"24_CR9","unstructured":"Dunton CJ (2003) Phase II study of weekly paclitaxel and weekly carboplatinum in recurrent platinum sensitive ovarian cancer. 2003 American Society of Clinical Oncology (ASCO) Annual Meeting. Proc Am Soc Clin Oncol 22, 467 (Abstract 1876)"},{"key":"24_CR10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","volume":"88","author":"LJ Havrilesky","year":"2003","unstructured":"Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clark-Pearson DL, Rodriguez GC, Carney ME (2003) Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 88:51\u201357","journal-title":"Gynecol Oncol"},{"key":"24_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1048-891X.2005.15006.x","volume":"15","author":"A Kikuchi","year":"2005","unstructured":"Kikuchi A, Sakamoto H, Yamamoto T (2005) Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. Int J Gynecol Cancer 15:45\u201349","journal-title":"Int J Gynecol Cancer"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-005-0024-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-005-0024-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-005-0024-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T04:42:17Z","timestamp":1586320937000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-005-0024-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s00404-005-0024-z","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,3]]}}}